Pear Therapeutics to Participate in BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Boston and San Francisco, February 10, 2021 – Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in an analyst-led fireside chat and a Prescription Digital Therapeutics panel discussion at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17.
The fireside chat will be at 11:30 a.m. ET and the panel discussion, “Prescription Digital Therapeutics Gain Momentum with the Promise of Better Outcomes for Patients: A Discussion with Three Pioneers,” will take place at 12:00 p.m. ET.
Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.
Media and Investors:
Director, Corporate Communications